SequelSEC

Vyome Holdings, Inc HIND

Pharmaceutical Preparations · CIK 0001427570 · Fiscal year ends 1231

Revenue
$129.72K
Fiscal year ended 2026-06-30
Operating income
-$11.92M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Vyome Holdings, Inc (HIND) reported revenue of $129.72K and net income of -$11.31M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Vyome Holdings, Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Vyome Holdings, Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$129.72K
Cost of revenue$61.30K
Gross profit$68.42K
Operating income-$11.92M
Net income-$11.31M
Research & development$1.59M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$2.68M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Vyome Holdings, Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$7.89M
Total assets$9.18M
Current assets$8.15M
Total liabilities$1.86M
Current liabilities$1.86M
Total equity incl. NCI$7.31M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$2.18K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$546.70K

Cash flow

Vyome Holdings, Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$5.58M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$13.15M
Net change in cash$7.50M
Stock-based compensation$566.88K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$10.71K

Derived

Vyome Holdings, Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin52.7%
Operating margin-9190.2%
FCF marginUnavailable
SBC / revenue437.0%
Current ratio4.37x
Revenue YoY growth-67.1%
Net margin-8716.8%
R&D / revenue1226.5%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HIND in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-18View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-20View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.